724 related articles for article (PubMed ID: 36469257)
1. Gut Microbiome and Its Impact on Obesity and Obesity-Related Disorders.
Sankararaman S; Noriega K; Velayuthan S; Sferra T; Martindale R
Curr Gastroenterol Rep; 2023 Feb; 25(2):31-44. PubMed ID: 36469257
[TBL] [Abstract][Full Text] [Related]
2. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives.
Vallianou N; Stratigou T; Christodoulatos GS; Dalamaga M
Curr Obes Rep; 2019 Sep; 8(3):317-332. PubMed ID: 31175629
[TBL] [Abstract][Full Text] [Related]
3. Modulating the Microbiota as a Therapeutic Intervention for Type 2 Diabetes.
Huda MN; Kim M; Bennett BJ
Front Endocrinol (Lausanne); 2021; 12():632335. PubMed ID: 33897618
[TBL] [Abstract][Full Text] [Related]
4. GUT MICROBIOTA, PREBIOTICS, PROBIOTICS, AND SYNBIOTICS IN MANAGEMENT OF OBESITY AND PREDIABETES: REVIEW OF RANDOMIZED CONTROLLED TRIALS.
Barengolts E
Endocr Pract; 2016 Oct; 22(10):1224-1234. PubMed ID: 27409822
[TBL] [Abstract][Full Text] [Related]
5. Gut Microbiota as a Therapeutic Target for Metabolic Disorders.
Okubo H; Nakatsu Y; Kushiyama A; Yamamotoya T; Matsunaga Y; Inoue MK; Fujishiro M; Sakoda H; Ohno H; Yoneda M; Ono H; Asano T
Curr Med Chem; 2018; 25(9):984-1001. PubMed ID: 28990516
[TBL] [Abstract][Full Text] [Related]
6. Gut Microbiota: An Important Player in Type 2 Diabetes Mellitus.
Zhou Z; Sun B; Yu D; Zhu C
Front Cell Infect Microbiol; 2022; 12():834485. PubMed ID: 35242721
[TBL] [Abstract][Full Text] [Related]
7. Understanding the gut microbiota in cancer cachexia.
Rocha IM; Fonseca DC; Torrinhas RSM; Waitzberg DL
Curr Opin Clin Nutr Metab Care; 2023 Sep; 26(5):482-489. PubMed ID: 37389459
[TBL] [Abstract][Full Text] [Related]
8. Gut Microbiota and Complications of Type-2 Diabetes.
Iatcu CO; Steen A; Covasa M
Nutrients; 2021 Dec; 14(1):. PubMed ID: 35011044
[TBL] [Abstract][Full Text] [Related]
9. Gut microbiota and obesity: An opportunity to alter obesity through faecal microbiota transplant (FMT).
Lee P; Yacyshyn BR; Yacyshyn MB
Diabetes Obes Metab; 2019 Mar; 21(3):479-490. PubMed ID: 30328245
[TBL] [Abstract][Full Text] [Related]
10. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
Suk KT; Kim DJ
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
[TBL] [Abstract][Full Text] [Related]
11. From role of gut microbiota to microbial-based therapies in type 2-diabetes.
Ebrahimzadeh Leylabadlo H; Sanaie S; Sadeghpour Heravi F; Ahmadian Z; Ghotaslou R
Infect Genet Evol; 2020 Jul; 81():104268. PubMed ID: 32126303
[TBL] [Abstract][Full Text] [Related]
12. Microbial dysbiosis-induced obesity: role of gut microbiota in homoeostasis of energy metabolism.
Amabebe E; Robert FO; Agbalalah T; Orubu ESF
Br J Nutr; 2020 May; 123(10):1127-1137. PubMed ID: 32008579
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic interventions for gut dysbiosis and related disorders in the elderly: antibiotics, probiotics or faecal microbiota transplantation?
Vemuri RC; Gundamaraju R; Shinde T; Eri R
Benef Microbes; 2017 Apr; 8(2):179-192. PubMed ID: 28008784
[TBL] [Abstract][Full Text] [Related]
14. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
[TBL] [Abstract][Full Text] [Related]
15. Diet, Gut Microbiota, and Obesity: Links with Host Genetics and Epigenetics and Potential Applications.
Cuevas-Sierra A; Ramos-Lopez O; Riezu-Boj JI; Milagro FI; Martinez JA
Adv Nutr; 2019 Jan; 10(suppl_1):S17-S30. PubMed ID: 30721960
[TBL] [Abstract][Full Text] [Related]
16. Targeting the gut microbiota and its metabolites for type 2 diabetes mellitus.
Wu J; Yang K; Fan H; Wei M; Xiong Q
Front Endocrinol (Lausanne); 2023; 14():1114424. PubMed ID: 37229456
[TBL] [Abstract][Full Text] [Related]
17. Gut microbiome and non-alcoholic fatty liver disease.
Purohit A; Alam MJ; Kandiyal B; Shalimar ; Das B; Banerjee SK
Prog Mol Biol Transl Sci; 2022; 191(1):187-206. PubMed ID: 36270678
[TBL] [Abstract][Full Text] [Related]
18. Different Strategies Targeting Gut Microbiota for the Management of Several Disorders: A Sustainable Approach.
Chowdhury M; Raj Chaudhary N; Kaur P; Goyal A; Sahu SK
Infect Disord Drug Targets; 2024; 24(5):e160124225675. PubMed ID: 38317473
[TBL] [Abstract][Full Text] [Related]
19. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
Cho MS; Kim SY; Suk KT; Kim BY
J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993
[TBL] [Abstract][Full Text] [Related]
20. Gut microbiota and host metabolism in liver cirrhosis.
Usami M; Miyoshi M; Yamashita H
World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
